U.S. Advocate Of Drug Quality Issues Says India DCGI Viewed As Corrupt
This article was originally published in PharmAsia News
A U.S. advocate of a stern approach toward drugs imported from India suggested the nation's drug regulator himself is part of the problem and "is seen as corrupt" by American physicians and patients.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.